Flora Growth (FLGC) Proxy Filing summary

Executive summary

• The proxy statement covers the 2024 Annual and Special Meeting, including key proposals, financial results, and the acquisition of TruHC Pharma GmbH, a German medical cannabis company with EU-GMP, GDP, and narcotics licenses.

• Flora Growth Corp. is focused on expanding its pharmaceutical distribution and consumer brands, with a strategic emphasis on the German and European cannabis markets.

• The company reported $76.1M in revenue for 2023, with a net loss of $56.3M, and continues to face challenges in achieving profitability and positive cash flow.

• The acquisition of TruHC is expected to strengthen Flora's position in Germany, diversify its business, and reduce reliance on existing subsidiaries.

• Management and auditors have raised substantial doubt about the company’s ability to continue as a going concern due to ongoing losses and limited liquidity.

Voting matters and shareholder proposals

• Election of four directors for a term expiring at the 2025 Annual Meeting.

• Re-appointment of Davidson & Company LLP as independent auditors for 2024.

• Amendment to the 2022 Incentive Compensation Plan to increase shares issuable from 950,000 to 2,500,000.

• Approval of Stock Appreciation Rights grants to the CEO and CFO, with vesting tied to significant share price increases.

• Approval of the issuance of 635,363 shares to acquire the minority interest in TruHC Pharma GmbH.

• Board recommends voting “FOR” all proposals.

Board of directors and corporate governance

• Board consists of four directors, with three considered independent under Nasdaq and Canadian standards.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, all chaired by independent directors.

• The company has adopted a Code of Conduct and Ethics and provides orientation and ongoing education for directors.

• No formal diversity policy, but board composition includes one diverse member.